Regulatory Accord, Intas, and Bio-Thera File Four IPRs Against Janssen Golimumab Patents Big Molecule WatchOn March 20, 2026, Accord BioPharma, Inc.RegulatoryImmunology & InflammationRead full story pharminent March 27, 2026 (Last updated: March 30, 2026) Big Molecule Watch On March 20, 2026, Accord BioPharma, Inc. RegulatoryImmunology & InflammationRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Otsuka picks up PTSD drug with $700M Transcend buyNext: S16 Ep38: Live Tumor Board: Precision Pathways Transforming Patient Care in Advanced NSCLC Related Stories Regulatory Japan approves Sanofi’s Sarclisa combo for MM treatment pharminent June 22, 2026 Regulatory FDA experts endorse Moderna’s mRNA seasonal flu shot pharminent June 19, 2026 Regulatory Moderna flu vaccine wins unanimous support from FDA panel pharminent June 18, 2026
